Applying Network Meta-Analysis to Cardiovascular Outcome Trials of Glucose-Lowering Drugs

被引：1
|
作者：
Zheng, Sean L. [1 ]
Roddick, Alistair J. [1 ]
机构：
[1] Imperial Coll London, Dept Cardiol, Fac Med, Kings Coll Hosp NHS Fdn Trust, 33 Willcott Rd, London SE5 9RS, England
来源：
JACC-HEART FAILURE | 2018年 / 6卷 / 12期
关键词：
D O I：
10.1016/j.jchf.2018.09.004
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1052 / 1052
页数：1
相关论文
共 50 条
  • [31] Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials
    Ghosh-Swaby, Olivia R.
    Goodman, Shaun G.
    Leiter, Lawrence A.
    Cheng, Alice
    Connelly, Kim A.
    Fitchett, David
    Juni, Peter
    Farkouh, Michael E.
    Udell, Jacob A.
    LANCET DIABETES & ENDOCRINOLOGY, 2020, 8 (05): : 418 - 435
  • [32] Glucose-lowering drugs and heart failure: implications of recent cardiovascular outcome trials in type 2 diabetes
    Cattadori, Gaia
    Pantanetti, Paola
    Ambrosio, Giuseppe
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2019, 157
  • [33] Design and Analysis of Diabetes Prevention Trials for Glucose-Lowering Drugs
    Holzhauer, Bjoern
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2014, 6 (01): : 104 - 114
  • [34] Cardiovascular safety concerns of glucose-lowering drugs
    Scholze J.
    MMW - Fortschritte der Medizin, 2017, 159 (1) : 62 - 66
  • [35] Cardiorenal Benefits of Newer Glucose-Lowering Drugs by Hispanic Ethnicity: A Meta-analysis of Results from Randomized Outcome Trials in Type 2 Diabetes
    Tang, Huilin
    Chen, Wei-Han
    Bian, Jiang
    O'Neal, Latoya J.
    Lackland, Daniel T.
    Schatz, Desmond
    Guo, Jingchuan
    DIABETES, 2022, 71
  • [36] Cardiovascular Outcomes Trials of Glucose-Lowering Drugs or Strategies in Type 2 Diabetes
    Gerstein, Hertzel C.
    Shah, Reema
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2018, 47 (01) : 97 - +
  • [37] Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes A Network Meta-Analysis
    Kramer, Caroline K.
    Ye, Chang
    Campbell, Sara
    Retnakaran, Ravi
    JACC-HEART FAILURE, 2018, 6 (10) : 823 - 830
  • [38] Effects of novel glucose-lowering drugs on the lipid parameters: A systematic review and meta-analysis
    Dar, Sophia
    Siddiqi, Ahmed Kamal
    Alabduladhem, Tamim Omar
    Rashid, Ahmed Mustafa
    Sarfraz, Saba
    Maniya, Talha
    Menezes, Ritesh G.
    Almas, Talal
    ANNALS OF MEDICINE AND SURGERY, 2022, 77
  • [39] Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs
    Alfayez, Osamah M.
    Al Yami, Majed S.
    Alshibani, Mohannad
    Fallatah, Saad B.
    Al Khushaym, Nasser M.
    Alsheikh, Razan
    Alkhatib, Nimer
    PRIMARY CARE DIABETES, 2019, 13 (03) : 204 - 211
  • [40] Glycaemic control and macrovascular and microvascular outcomes in type 2 diabetes: Systematic review and meta-analysis of cardiovascular outcome trials of novel glucose-lowering agents
    Kunutsor, Setor K.
    Zaccardi, Francesco
    Balasubramanian, Victoria G.
    Gillies, Clare L.
    Aroda, Vanita R.
    Seidu, Samuel
    Davies, Melanie J.
    Khunti, Kamlesh
    DIABETES OBESITY & METABOLISM, 2024, 26 (05): : 1837 - 1849
12345